ES2177089T3 - Fosfolipidos con actividad antimicrobiana en presencia de antimicrobianos. - Google Patents

Fosfolipidos con actividad antimicrobiana en presencia de antimicrobianos.

Info

Publication number
ES2177089T3
ES2177089T3 ES98956826T ES98956826T ES2177089T3 ES 2177089 T3 ES2177089 T3 ES 2177089T3 ES 98956826 T ES98956826 T ES 98956826T ES 98956826 T ES98956826 T ES 98956826T ES 2177089 T3 ES2177089 T3 ES 2177089T3
Authority
ES
Spain
Prior art keywords
antimicrobials
phospholipids
antimicrobial activity
antimicrobial
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956826T
Other languages
English (en)
Inventor
Paul S Cohen
Karen A Krogfelt
David C Laux
Maryjane Utley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Application granted granted Critical
Publication of ES2177089T3 publication Critical patent/ES2177089T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Combinación de a) una substancia de fórmula general (I): **(Fórmula)** en la que Z representa un residuo oxiácido de fósforo o azufre; uno de R1 y R2 representa un grupo hidroxi y el otro de R1 y R2 representa un residuo de ácido graso no saturado con un mínimo de 7 átomos de carbono; y R3 representa un hidrógeno; y b) un antimicrobiano para utilización como medicamento.
ES98956826T 1997-11-20 1998-11-20 Fosfolipidos con actividad antimicrobiana en presencia de antimicrobianos. Expired - Lifetime ES2177089T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6690197P 1997-11-20 1997-11-20

Publications (1)

Publication Number Publication Date
ES2177089T3 true ES2177089T3 (es) 2002-12-01

Family

ID=22072448

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956826T Expired - Lifetime ES2177089T3 (es) 1997-11-20 1998-11-20 Fosfolipidos con actividad antimicrobiana en presencia de antimicrobianos.

Country Status (11)

Country Link
US (1) US6165997A (es)
EP (1) EP1051180B1 (es)
JP (1) JP2001523723A (es)
AT (1) ATE216585T1 (es)
AU (1) AU747288B2 (es)
CA (1) CA2316340A1 (es)
DE (1) DE69805100T2 (es)
DK (1) DK1051180T3 (es)
ES (1) ES2177089T3 (es)
NZ (1) NZ505233A (es)
WO (1) WO1999026632A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
AU1223099A (en) * 1997-11-24 1999-06-15 Zhongming Zeng Pharmaceutical formulation for stimulating the growth of gram-positive bacil li and increasing the acidity in vagina and the use thereof
GB9827865D0 (en) * 1998-12-18 1999-02-10 Woodcock Fiona Medicament
US6838480B1 (en) * 1999-05-28 2005-01-04 Marie Madeline Wharton Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
US6964949B2 (en) * 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
JP2004526803A (ja) * 2001-04-25 2004-09-02 バイオサイナーゲン、インコーポレーテッド リゾフォスファチジン酸を含む薬剤学的組成物(apharmaceuticalcompositioncomprisinglysophosphatidicacid)
WO2002096354A2 (en) 2001-05-29 2002-12-05 Tap Pharmaceutical Products Inc. Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
GB0201028D0 (en) * 2002-01-17 2002-03-06 Britannia Pharmaceuticals Ltd Prevention of infectious diseases
ITMI20021280A1 (it) * 2002-06-11 2003-12-11 Carlo Ghisalberti Metodo di trattamento anticellulite
US20050036972A1 (en) * 2003-03-10 2005-02-17 Hy-Gene Biomedical Corporation System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations
UA89545C2 (uk) * 2005-08-29 2010-02-10 Сепсикюр Л.Л.К. Спосіб лікування чи попередження станів, викликаних грампозитивними бактеріями
EP1869981A1 (de) * 2006-06-21 2007-12-26 Staatliches Weinbauinstitut Freiburg Alkylphospholipide und Lyso-Phospholipide zur Bekämpfung von Pflanzenpathogenen
KR100870232B1 (ko) * 2006-12-07 2008-11-24 재단법인서울대학교산학협력재단 치아용 미백기능성 물질 전달시스템
JP5468385B2 (ja) * 2007-11-02 2014-04-09 ナガセケムテックス株式会社 抗真菌剤及び抗菌剤
US20090149395A1 (en) * 2007-12-10 2009-06-11 Peoples Aaron Novel macrocyclic polyene lactams
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
GB2486371A (en) * 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
US9693564B2 (en) * 2011-06-21 2017-07-04 Safehands Solutions, LLC Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
KR101315483B1 (ko) * 2011-06-23 2013-10-07 주식회사 아리바이오 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
EP2805612A1 (en) 2013-05-22 2014-11-26 University of Graz Lysophospholipids against American Foulbrood
US11660344B2 (en) * 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
CN105682663B (zh) 2013-11-28 2019-08-02 丘比株式会社 多重耐药革兰氏阳性菌抗菌剂及外用剂
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
WO2019060761A1 (en) * 2017-09-21 2019-03-28 The Scripps Research Institute NEW THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINO-SINUSITIS
KR102641583B1 (ko) * 2018-10-23 2024-02-28 건국대학교 산학협력단 지도부딘을 포함하는 식물병 방제용 조성물
WO2023111173A1 (en) * 2021-12-16 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2185249A5 (es) * 1972-05-15 1973-12-28 Ibm
JPS5318581B2 (es) * 1974-03-12 1978-06-15
JPS5233139A (en) * 1975-09-08 1977-03-14 Masakane Katayama Automatic gas stop safety device with annunciator
JPS53118523A (en) * 1977-03-23 1978-10-17 Rikagaku Kenkyusho Fungicides for agriculture and horticulture, and composition for controlling agents against fruit pests during storage
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
CA1237670A (en) * 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
JPS6055564A (ja) * 1983-09-06 1985-03-30 Toshiba Corp エラ−訂正回路
US5135922A (en) * 1984-06-15 1992-08-04 Med-Tal, Inc. Prevention and treatment of microbial infection by phosphoglycerides
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
JPS6216431A (ja) * 1985-07-15 1987-01-24 Nakanishi Michio 医薬組成物
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
JPH0774132B2 (ja) * 1986-10-06 1995-08-09 旭電化工業株式会社 界面活性を有する静菌性組成物
NZ223660A (en) * 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
ATE113468T1 (de) * 1987-07-29 1994-11-15 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US5624958A (en) * 1987-12-31 1997-04-29 Isaacs; Charles E. Disinfecting contact lenses
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
FR2636331B1 (fr) * 1988-09-12 1990-11-16 Bioeurope Procede de preparation d'acides lysophosphatidiques et de sels de ceux-ci
US4999199A (en) * 1988-11-10 1991-03-12 Board Of Regents, The University Of Texas System Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
JP2794072B2 (ja) * 1989-09-29 1998-09-03 株式会社ヤクルト本社 抗菌剤
ATE124262T1 (de) * 1990-12-21 1995-07-15 Microcarb Inc Verwendung von wirtszellphospholipiden zur hemmung bakterieller besiedlung.
IT1247165B (it) * 1991-03-15 1994-12-12 Fidia Spa Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.
US5648348A (en) * 1991-10-28 1997-07-15 Mona Industries, Inc. Phospholipid antimicrobial compositions
AU662367B2 (en) * 1991-10-28 1995-08-31 Mona Industries, Inc. Phospholipid antimicrobial compositions
FR2683721B1 (fr) * 1991-11-15 1995-06-09 Inocosm Laboratoires Composition lipidique polaire permettant de vehiculer un agent actif et/ou de le faire penetrer dans une cellule cible.
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP2604940B2 (ja) * 1992-05-19 1997-04-30 株式会社リケン イオンプレーティング用蒸発材
JP2809573B2 (ja) * 1993-03-08 1998-10-08 科学技術振興事業団 新規リゾホスファチジルイノシトール及びその製造法
US5478819A (en) * 1993-06-23 1995-12-26 Simo Tarpila Phospholipid composition and use thereof
US5480877A (en) * 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
JPH07147953A (ja) * 1993-11-29 1995-06-13 Yakult Honsha Co Ltd 抗菌剤及び抗菌剤の使用方法
WO1995032716A1 (en) * 1994-05-31 1995-12-07 Haar, Jonathan Methods and products for the control of pathogenic bacteria
WO1995035091A1 (en) * 1994-06-21 1995-12-28 Institute For Advanced Skin Research Inc. Skin activator having glycosaminoglycan production accelerator activity
FR2745184A1 (fr) * 1996-02-28 1997-08-29 Chanseau Sylvain Utilisation de la lecithine de soja pour la preparation d' un medicament contre le sida

Also Published As

Publication number Publication date
DK1051180T3 (da) 2002-08-19
CA2316340A1 (en) 1999-06-03
DE69805100T2 (de) 2002-12-05
US6165997A (en) 2000-12-26
EP1051180A1 (en) 2000-11-15
DE69805100D1 (de) 2002-05-29
WO1999026632B1 (en) 1999-07-22
ATE216585T1 (de) 2002-05-15
EP1051180B1 (en) 2002-04-24
WO1999026632A1 (en) 1999-06-03
JP2001523723A (ja) 2001-11-27
NZ505233A (en) 2002-07-26
AU747288B2 (en) 2002-05-16
AU1333799A (en) 1999-06-15
WO1999026632A8 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
ES2177089T3 (es) Fosfolipidos con actividad antimicrobiana en presencia de antimicrobianos.
BR9911431A (pt) Processo para produção de uma solução aquosa de ácido monoéster peroxicarboxìlico
ES2032899T3 (es) Agente cosmetico para aplicacion externa y su uso.
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
ES2177422A1 (es) Composiciones acaricidas.
PE20001646A1 (es) BIFENILO QUE CONTIENEN COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE aP2
BR9406256A (pt) Processo para a preparação de uma composição aquosa desinfetante composição desinfetante sistema de duas embalagens para a preparação de uma composição desinfetante
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
BR0312882A (pt) Derivados de pleuromutilina como antimicrobianos
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
ES2093944T3 (es) Composicion cosmetica y/o dermatologica de accion despigmentante que contiene un acido di- o tri-cafeoilquinico o una mezcla de estos.
ES2117132T3 (es) Sales de desferrioxamina-b y su uso como queladores de hierro eficaces por via oral.
GT199800081A (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para el tratamiento delcancer.
MX9703339A (es) Solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
ES2019554A6 (es) Procedimiento para preparar n,n -ditrimetoxibenzoilpiperazinas sustituidas en posicion 2"
ES2039719T3 (es) Procedimiento para preparar un agente terapeutico para el tratamiento de la enfermedad de ulcera peptica.
ES2175419T3 (es) Preparacion farmaceutica que contiene nimesulida para uso topico.
DE59803437D1 (de) Aldehydfreie desinfektionsmittel für flächen und instrumente
MX9102192A (es) Mejoras en compuestos de piperazinoalquilbenzoxazina y piperazinoalquilbenzotiazin sustituidos con un heterociclo, asi como procedimiento para su preparacion.
DE59914636D1 (de) Stabilisierung von biologischen Flüssigkeiten durch Zusatz von Sterinestern